EGFR and metastatic neoplasm: The lung tumors with lymphatic spreading were enriched with mutations in EGFR (P = 4E-03) and TP53 (P = 1.3E-02) (Table 2 and Fig. S5), indicating that tumors with EGFR or TP53 mutations were more likely to develop metastatic tumors and might have poorer prognosis.